Table 1 Pre-treatment characteristics and treatment duration in CHB patients with or without off-treatment sustained virologic remission

Number

95

16

79

Age

47 (21–76)

45 (36–63)

49 (21–76)

0.242

Male (%)

53 (55.8)

9 (56.2)

44 (55.7)

0.968

Oral nucleos(t)ide

Entecavir

67

8

59

Lamivudine

15

5

10

0.110

Clevudine

13

3

10

HBeAg (pos/neg)

41/54

6/10

35/44

0.616

HBeAb seroconversion^b before NA discontinuation

24

4

20

0.659

Alanine aminotransferase, xupper limit of normal

4.9 (0.4–30.8)

7.9 (1.1–30.8)

4.3 (0.4–25.4)

0.121

Prothrombin time, INR (range)

1.1 (1.0–1. 6)

1.1 (1.0–1.5)

1.1 (1.0–1.6)

0.704

HBV DNA (log IU/ml)

6.54 (3.31–8.00)

6.47 (3.31–8.00)

6.20 (3.44–8.00)

0.146

Cirrhosis

44 (46.4)

10 (62.5)

34 (45.0)

0.155

Total treatment duration (months)

22 (12–56)

28 (14–43)

22 (12–56)

0.016

Time to undetectable HBV DNA (months)

6 (1–23)

4 (2–6)

4 (1–23)

0.908

Additional treatment after HBeAg loss (months)^b

14 (6–47)

16 (11–21)

13 (6–47)

0.988

Additional treatment after HBV DNA clearance^c

16 (12–40)

25 (15–40)

17 (12–40)

0.001